Gleevec (Imatinib 400mg) Global Pricing Disparity Workbench

30-Tablet Monthly Regimen: US Brand List ($9,850) vs Direct Cash Generic ($47) vs India Retail ($65)
● Model Active
US Brand List vs India Ratio
151.5x
US List $9,850/mo vs India $65/mo ($15,053% premium)
US Annual Brand Exposure
$118,200
Includes $46,200/yr intermediated PBM rebates
Direct Cash Generic Alternative
$564 / yr
Cost Plus / Generic Cash ($47/mo for 30 tabs)
Indian National Generic Cost
$780 / yr
Supreme Court Sec 3(d) Patent Ruling outcome
US Supply-Chain Margin Decomposition
Manufacturer Net Realization: $4,150
PBM Rebates & Formulary Fees: $3,850
Wholesaler / Distributor Markup: $650
Pharmacy Margin & Dispensing Fee: $1,200
Supply-Chain Margin Verdict: Out of the $9,850 monthly US list price, $3,850 (39.1%) is absorbed by PBM gross rebates, while the net manufacturer revenue is $4,150 (42.1%).
Interactive Waterfall Breakdown (30x 400mg Tablets) Total List: $9,850
Global Price & Policy Comparison (Imatinib 400mg)
Jurisdiction / Channel Pack Price Pricing Framework Status
Chronic Myelogenous Leukemia (CML) Patient Cost Simulator US HDHP Plan
Insurance Coinsurance Rate: 20%
Annual Out-of-Pocket Max / Deductible: $9,100
Treatment Timeline US Brand (Insured) US Generic Cash India Generic
Clinical Reality: CML patients require continuous lifelong daily imatinib therapy. In the US, patients quickly hit catastrophic out-of-pocket maximums every single January, whereas Indian or direct generic cash buyers pay less than 1/10th of the annual deductible.
Gleevec® (imatinib mesylate) 400mg pricing data calibrated to US Red Book AWP/WAC benchmarks, Mark Cuban Cost Plus Drugs, India NPPA retail caps (Novartis v. Union of India, 2013), and UK NHS BNF reference datasets.
Enjoy this tool? Build your own with Super